Report from the Annual General Meeting in AQILION AB
Helsingborg, Sweden – June 18, 2021 – AQILION AB (publ) held its Annual General Meeting today on June 18, 2021, during which the Meeting resolved in accordance with the proposals set forth by the Board of Directors and the Nomination Committee. The complete details of the proposed resolutions can be found in the Notice to attend the Annual General Meeting.
Adoption of income statement and balance sheet, as well as allocation of result
The Annual General Meeting resolved to adopt the annual accounts with income statement and balance sheet for the 2020 financial year. The Meeting resolved that the entire amount at the disposal of the Meeting would be carried forward.
Dividend
The Annual General Meeting resolved that no dividend would be paid for the 2020 financial year.
Discharge from liability
The Annual General Meeting resolved to discharge the Directors of the Board and the Chief Executive Officer from liability for the 2020 financial year.
Nomination Committee
The Nomination Committee for the 2021 Annual General Meeting of AQILION AB consisted of Christian Ewe (chair), Helena Arcombe, Linnea Höglund och Malin Ruijsenaars.
Determination of fees for the members of the Board of Directors and the auditors
The Annual General Meeting resolved to pay fees until the close of the next Annual General Meeting in the amount of SEK 210,000 to the Chairman of the Board and SEK 90,000 for each Director of the Board who is not employed by the company. Remuneration to the auditor will be paid on approved account.
Determination of the number of Board Members and election of the Board
The Meeting resolved that the Board will consist of six members without deputies. The following individuals were elected to serve on the Board until the next Annual General Meeting: Roland Andersson (reelection), Marie Lidgard (reelection), Johan Lund (reelection), Martin Olovsson (reelection), Gunilla Savring (new election) and Andreas Segerros (reelection). Johan Lund was elected to serve as Chairman of the Board.
Election of auditor
Mazars AB Helsingborg with authorized public accountant Andreas Brodström and Bertil Toresson as co-auditor were reelected to serve until the next Annual General Meeting.
Adoption of guidelines for remuneration to senior executives
The Annual General Meeting resolved in accordance with the Board’s proposal.
Adoption of principles for appointing the Nomination Committee and the task of the Nomination Committee
The Annual General Meeting resolved in accordance with the Board’s proposal. The resolution on instructions for the Nomination Committee shall be in effect until such time that the Annual General Meeting decides otherwise.
Authorization decision
The Annual General Meeting resolved in accordance with the Board’s proposal of an authorization for the Board of Directors to resolve on the issuance of shares, convertibles and/or warrants.
For more information, please contact
Sarah Fredriksson
CEO, AQILION AB
+46 (0)70 261 4575
sarah.fredriksson@aqilion.com
About Aqilion
Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.
Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion’s experienced team and board have successfully shepherded drugs all the way from discovery to market.
AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com
Tags: